Propofol infusion syndrome

• Published in: Anaesthesia 2007-07, Vol.62 (7), p.690-701
• Main Authors: Kam, P. C. A., Cardone, D.
• Format: Article
• Language: English
• Subjects: Acidosis - chemically induced; Adolescent; Adult; Anesthesia; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Anesthetics, Intravenous - adverse effects; Biological and medical sciences; Biomarkers - blood; Bradycardia - chemically induced; Bradycardia - physiopathology; Bradycardia - therapy; Child; Child, Preschool; Death, Sudden - etiology; Female; Humans; Hypnotics and Sedatives - adverse effects; Infant; Male; Medical sciences; Mitochondrial Diseases - chemically induced; Propofol - adverse effects; Risk Factors; Syndrome
• ISSN: 0003-2409; 1365-2044
• DOI: 10.1111/j.1365-2044.2007.05055.x

Summary The clinical features of propofol infusion syndrome (PRIS) are acute refractory bradycardia leading to asystole, in the presence of one or more of the following: metabolic acidosis (base deficit > 10 mmol.l−1), rhabdomyolysis, hyperlipidaemia, and enlarged or fatty liver. There is an association between PRIS and propofol infusions at doses higher than 4 mg.kg−1.h−1 for greater than 48 h duration. Sixty‐one patients with PRIS have been recorded in the literature, with deaths in 20 paediatric and 18 adult patients. Seven of these patients (four paediatric and three adult patients) developed PRIS during anaesthesia. It is proposed that the syndrome may be caused by either a direct mitochondrial respiratory chain inhibition or impaired mitochondrial fatty acid metabolism mediated by propofol. An early sign of cardiac instability associated with the syndrome is the development of right bundle branch block with convex‐curved (‘coved type’) ST elevation in the right praecordial leads (V1 to V3) of the electrocardiogram. Predisposing factors include young age, severe critical illness of central nervous system or respiratory origin, exogenous catecholamine or glucocorticoid administration, inadequate carbohydrate intake and subclinical mitochondrial disease. Treatment options are limited. Haemodialysis or haemoperfusion with cardiorespiratory support has been the most successful treatment.